ORG Wealth Partners LLC Purchases New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

ORG Wealth Partners LLC acquired a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 3rd quarter, Holdings Channel reports. The fund acquired 2,252 shares of the biopharmaceutical company’s stock, valued at approximately $53,000.

Other large investors also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC purchased a new position in shares of TG Therapeutics in the 2nd quarter worth approximately $35,000. DekaBank Deutsche Girozentrale purchased a new position in TG Therapeutics during the first quarter worth $58,000. Lazard Asset Management LLC bought a new position in TG Therapeutics during the first quarter valued at $91,000. nVerses Capital LLC raised its stake in shares of TG Therapeutics by 34.9% in the second quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 1,500 shares during the period. Finally, Quarry LP raised its stake in shares of TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock valued at $107,000 after acquiring an additional 503 shares during the period. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Price Performance

Shares of TGTX opened at $24.57 on Wednesday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.83 and a current ratio of 3.58. The company has a 50 day moving average price of $22.95 and a 200-day moving average price of $19.19. TG Therapeutics, Inc. has a fifty-two week low of $6.46 and a fifty-two week high of $26.41. The stock has a market capitalization of $3.80 billion, a PE ratio of 106.83 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. The business had revenue of $73.47 million for the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business’s revenue was up 357.0% compared to the same quarter last year. During the same period last year, the business posted ($0.34) EPS. Equities analysts predict that TG Therapeutics, Inc. will post 0.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TGTX has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating and issued a $49.00 price objective on shares of TG Therapeutics in a research note on Wednesday, September 18th. The Goldman Sachs Group boosted their price objective on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Finally, B. Riley increased their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $31.83.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.